Supernus Pharmaceuticals, Inc. (SUPN) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SUPN Revenue Growth
Revenue Breakdown (FY 2025)
SUPN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
SUPN Revenue Analysis (2014–2025)
As of May 8, 2026, Supernus Pharmaceuticals, Inc. (SUPN) generated trailing twelve-month (TTM) revenue of $776.8 million, reflecting explosive growth of +38.6% year-over-year. The most recent quarter (Q1 2026) recorded $207.7 million in revenue, down 1.8% sequentially.
Looking at the longer-term picture, SUPN's 5-year compound annual growth rate (CAGR) stands at +6.7%, indicating steady revenue expansion. The company achieved its highest annual revenue of $719.0 million in 2025, representing a new all-time high.
Revenue diversification analysis shows SUPN's business is primarily driven by Product (47%), Qelbree (23%), and GOCOVRI (11%).
When compared to Healthcare sector peers including PCRX (+4.6% YoY), ACAD (+9.9% YoY), and INVA (+13.6% YoY), SUPN has outperformed the peer group in terms of revenue growth. Compare SUPN vs PCRX →
SUPN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SUPNCurrent | $777M | +38.6% | +6.7% | -5.1% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 LNTH | $1.5B | +0.6% | +35.3% | 20.2% |
SUPN Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $719.0M | +8.6% | $644.4M | 89.6% | $-36,864,000 | -5.1% |
| 2024 | $661.8M | +8.9% | $583.9M | 88.2% | $81.7M | 12.3% |
| 2023 | $607.5M | -8.9% | $523.7M | 86.2% | $-5,269,000 | -0.9% |
| 2022 | $667.2M | +15.1% | $580.0M | 86.9% | $46.1M | 6.9% |
| 2021 | $579.8M | +11.4% | $504.7M | 87.1% | $86.0M | 14.8% |
| 2020 | $520.4M | +32.5% | $467.9M | 89.9% | $173.7M | 33.4% |
| 2019 | $392.8M | -3.9% | $376.1M | 95.8% | $148.6M | 37.8% |
| 2018 | $408.9M | +35.3% | $393.5M | 96.2% | $144.4M | 35.3% |
| 2017 | $302.2M | +40.6% | $287.0M | 95.0% | $99.5M | 32.9% |
| 2016 | $215.0M | +48.9% | $203.0M | 94.4% | $54.2M | 25.2% |
See SUPN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SUPN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SUPN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSUPN — Frequently Asked Questions
Quick answers to the most common questions about buying SUPN stock.
Is SUPN's revenue growth accelerating or slowing?
SUPN revenue is accelerating at +38.6% year-over-year, exceeding the 5-year CAGR of +6.7%. TTM revenue reached $777M. Growth momentum has increased versus prior periods.
What is SUPN's long-term revenue growth rate?
Supernus Pharmaceuticals, Inc.'s 5-year revenue CAGR of +6.7% reflects the sustained expansion pattern. Current YoY growth of +38.6% is above this long-term average.
How is SUPN's revenue distributed by segment?
SUPN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.